

S3 Table. Clinical outcomes of patients according to the regimen of immune-checkpoint inhibitor

Characteristic	Nivolumab (n=153)	Pembrolizu mab (n=79)	Atezolizu mab (n=5)	Avelumab (n=1)	Nivolumab +ipilimuma b (n=4)	p-value
CR	1 (0.7)	0	0	0	0	0.903
PR	21 (13.7)	15 (19.0)	0	0	0	
SD	9 (5.9)	4 (5.1)	1 (20.0)	0	0	
PD	114 (74.5)	53 (67.1)	4 (80.0)	1 (100)	3 (75.0)	
Not evaluated	8 (5.2)	7 (8.9)	0	0	1 (25.0)	
OS, median (day) ^{a)}	969	Not reached	204	Not reached	94	0.165
PFS, median (day) ^{b)}	57	78	26	17	119	0.682

Values are presented as number (%). CR, complete response; ICI, immune checkpoint inhibitor; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease. ^{a)}Defined as days from the first administration of ICI to death, ^{b)}Defined as days from the first administration of ICI to progression or death.